Abstract
BackgroundTofacitinib (CP-690,550) is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator in rheumatoid arthritis (RA).ObjectivesTo describe and report the incidence of gastrointestinal (GI) adverse events (AEs)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have